Articles

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
Baylor University Medical Center, Dallas, TX
University of Michigan Rogel Cancer Center, Ann Arbor, MI
University of Michigan Rogel Cancer Center, Ann Arbor, MI
Duke University School of Medicine, Durham, NC
University of Cincinnati Cancer Center, Cincinnati, OH
Weill Cornell Medical College, New York, NY
Winship Cancer Institute of Emory University, Atlanta, GA
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA
Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA
Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA
Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA
Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA
Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA
Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
Haematologica Early view Oct 13, 2022 https://doi.org/10.3324/haematol.2022.281216